XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
STATEMENTS OF STOCKHOLDERS' DEFICIT - 3 months ended May 31, 2016 - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 29, 2016 $ 131,449 $ 117,036,345 $ (117,268,812) $ (101,018)
Balance (in shares) at Feb. 29, 2016 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties   75,592   75,592
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.   333,437   333,437
Net loss     (369,953) (369,953)
Balance at May. 31, 2016 $ 131,449 $ 117,445,374 $ (117,638,765) $ (61,942)
Balance (in shares) at May. 31, 2016 131,448,444